Rogcon Biosciences Inc., of New Haven, Conn., partnered with Prometheus Research to support the creation of a clinical data registry to assist a planned international natural history study of patients with SCN2A mutations, which Rogcon said are the most common cause of neurodevelopmental disease including epilepsy and autism.